Table 4. Relationship between history of CAD and LDL-C level at first measurement after hospitalization among patients overall and according to lipid-lowering therapy.

	History of CAD§				No history of CAD§				Statistical tests# (patients with/without CAD), p values
	n	Mean ± SD LDL-C mg/dL	< 100 mg/dL (< 2.59 mmol/L) (%)	< 70 mg/dL (< 1.81 mmol/L) (%)	n	Mean ± SD LDL-C mg/dL	< 100 mg/dL (< 2.59 mmol/L) (%)	< 70 mg/dL (< 1.81 mmol/L) (%)	Mean difference (Student's t-test)	Rates of LDL-C < 100 mg/dL (Fisher's exact test)
All patients at hospitalization	332	103.6 ± 38.0	173 (52.1)	50 (15.1)	1495	125.1 ± 39.0	380 (25.4)	70 (4.7)	< 0.001	< 0.001
No lipid-lowering therapy	116	120.6 ± 40.5	37 (31.9)	11 (9.5)	1131	130.1 ± 39.6	234 (20.7)	41 (3.6)	0.014	0.009
Any lipid-lowering therapy	216	94.5 ± 33.3	136 (63.0)	39 (18.1)	364	109.6 ± 32.9	146 (40.1)	29 (8.0)	< 0.001	< 0.001
Any statin therapy	196	93.1 ± 33.2	128 (65.3)	39 (19.9)	294	107.5 ± 31.3	125 (42.5)	25 (8.5)	< 0.001	< 0.001
Intensive statin therapy†	12	96.2 ± 35.2	7 (58.3)	2 (16.7)	16	112.9 ± 34.1	5 (31.3)	0 (0.0)	-	-
Fibrate therapy	5	93.0 ± 16.5	2 (40.0)	0 (0.0)	27	118.9 ± 29.1	5 (18.5)	2 (7.4)	-	-
Ezetimibe therapy	14	105.9 ± 44.2	6 (42.9)	3 (21.4)	22	109.0 ± 47.2	9 (40.9)	6 (27.3)	-	-
EPA/DHA therapy	23	83.3 ± 31.9	16 (69.6)	6 (26.1)	41	108.0 ± 31.6	18 (43.9)	4 (9.8)	-	-
Other lipid-lowering therapy (no PCSK9i)	20	100.2 ± 32.1	11 (55.0)	2 (10.0)	29	110.5 ± 49.5	14 (48.3)	4 (13.8)	-	-

^§Patients with available LDL-C level at the time of ACS diagnosis.

^#Statistical comparisons were carried out only for n ≥ 100.

^†Intensive statin therapy was defined as atorvastatin ≥ 20 mg, rosuvastatin ≥ 10 mg, or pitavastatin ≥ 4 mg.

Conversion factor for LDL-C from mg/dL to mmol/L, 0.0259.

ACS, acute coronary syndrome; CAD, coronary artery disease; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LDL-C, low-density lipoprotein cholesterol; PCSK9i, proprotein convertase subtilisin/kexin 9 inhibitor; SD, standard deviation